Two Sigma Securities, LLC Savara Inc Transaction History

Two Sigma Securities, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.1 - $1.58 $11,019 - $15,828	-10,018 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.05 - $1.36 $10,518 - $13,624	10,018 New	10,018 $13,000
Q1 2018 May 15, 2018	SELL	$8.99 - $14.95 $104,796 - $174,272	-11,657 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$8.26 - $16.76 $96,286 - $195,371	11,657	11,657 $173,000

129

158M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $357M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Two Sigma Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Securities, LLC with notifications on news.